Overall, at 48 weeks, Descovy was associated with more favourable changes in eGFR and markers of proximal tubular function compared with Truvada, and proteinuria (protein in the urine) was less common (24% vs 21%, respectively), Dr Mills reported.
Go to: https://www.medsengage.com/blog/descovy-vs-truvada/
